With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play a more prominent role this year.

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

UK investment bank Peel Hunt suggests food inflation could near 4% by the end of 2025 as supermarkets react to cost pressures arising from Labour’s budget in October.

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...